These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

687 related items for PubMed ID: 11960336

  • 1. Less intense conditioning with fludarabine, cyclophosphamide, idarubicin and etoposide (FCIE) followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemia.
    Schlenk RF, Hartmann F, Hensel M, Jung W, Weber-Nordt R, Gabler A, Haas R, Ho AD, Trümper L, Döhner H.
    Leukemia; 2002 Apr; 16(4):581-6. PubMed ID: 11960336
    [Abstract] [Full Text] [Related]

  • 2. The graft-versus-leukemia effect of nonmyeloablative stem cell allografts may not be sufficient to cure chronic myelogenous leukemia.
    Sloand E, Childs RW, Solomon S, Greene A, Young NS, Barrett AJ.
    Bone Marrow Transplant; 2003 Nov; 32(9):897-901. PubMed ID: 14561990
    [Abstract] [Full Text] [Related]

  • 3. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A, Iori A, Guglielmi C, Romano A, Cerretti R, Torromeo C, Micozzi A, Fenu S, Laurenti L, Donato V, De Felice L, Arcese W.
    Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
    [Abstract] [Full Text] [Related]

  • 4. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N, Bornhäuser M, Ehninger G, Schwerdtfeger R, Biersack H, Sayer HG, Wandt H, Schäfer-Eckardt K, Beyer J, Kiehl M, Zander AR, German Cooperative Transplant Study Group.
    Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
    [Abstract] [Full Text] [Related]

  • 5. [Peripheral blood hematopoietic cell transplant using immunosuppressive chemotherapy without bone marrow destruction: "minitransplant"].
    Gómez-Almaguer D, Ruiz-Argüelles GJ, González-Llano O, Ruiz-Argüelles A, Cantú-Rodríguez OG.
    Gac Med Mex; 2002 Jun; 138(3):235-9. PubMed ID: 12096391
    [Abstract] [Full Text] [Related]

  • 6. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
    Lemoli RM, Visani G, Leopardi G, Motta MR, Rizzi S, Testoni N, Curti A, Tura S.
    Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254
    [Abstract] [Full Text] [Related]

  • 7. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
    Kröger N, Zabelina T, Sonnenberg S, Krüger W, Renges H, Stute N, Finkenstein F, Mayer U, Holstein K, Fiedler W, Colberg H, Sonnen R, Kuse R, Braumann D, Metzner B, del Valle F, Erttmann R, Kabisch H, Zander AR.
    Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
    [Abstract] [Full Text] [Related]

  • 8. Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease.
    Anderlini P, Giralt S, Andersson B, Ueno NT, Khouri I, Acholonu S, Cohen A, Körbling MJ, Manning J, Romaguera J, Sarris A, Rodriguez, Hagemeister F, Mclaughlin P, Cabanillas F, Champlin RE.
    Bone Marrow Transplant; 2000 Sep; 26(6):615-20. PubMed ID: 11041566
    [Abstract] [Full Text] [Related]

  • 9. Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies.
    Cao TM, Kusnierz-Glaz C, Valone F, Stockerl-Goldstein KE, Hu WW, Johnston L, Blume KG, Strober S, Negrin RS.
    Cancer; 2001 Jun 15; 91(12):2205-13. PubMed ID: 11413507
    [Abstract] [Full Text] [Related]

  • 10. Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.
    Saure C, Schroeder T, Zohren F, Groten A, Bruns I, Czibere A, Galonska L, Kondakci M, Weigelt C, Fenk R, Germing U, Haas R, Kobbe G.
    Biol Blood Marrow Transplant; 2012 Mar 15; 18(3):466-72. PubMed ID: 21963618
    [Abstract] [Full Text] [Related]

  • 11. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
    Gürman G, Arat M, Ilhan O, Konuk N, Beksaç M, Celebi H, Ozcan M, Arslan O, Ustün C, Akan H, Uysal A, Koç H.
    Cytotherapy; 2001 Mar 15; 3(4):253-60. PubMed ID: 12171713
    [Abstract] [Full Text] [Related]

  • 12. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
    Liu QF, Fan ZP, Zhang Y, Jiang ZJ, Wang CY, Xu D, Sun J, Xiao Y, Tan H.
    Biol Blood Marrow Transplant; 2009 Nov 15; 15(11):1376-85. PubMed ID: 19822296
    [Abstract] [Full Text] [Related]

  • 13. Fludarabine-based conditioning chemotherapy for allogeneic hematopoietic stem cell transplantation in acquired severe aplastic anemia.
    Al-Zahrani H, Nassar A, Al-Mohareb F, Al-Sharif F, Mohamed S, Al-Anazi K, Patel M, Rasheed W, Saleh AJ, Bakr M, Ahmed S, Ibrahim K, Hussain F, Elkum N, Elhassan T, Nurgat Z, Chaudhri N, Aljurf M.
    Biol Blood Marrow Transplant; 2011 May 15; 17(5):717-22. PubMed ID: 20736079
    [Abstract] [Full Text] [Related]

  • 14. Allogeneic blood stem cell transplantation in chronic myeloid leukaemia-chronic phase following conditioning with busulphan and cyclophosphamide: a follow up report.
    Saikia TK, Parikh PM, Tawde S, Amare-Kadam PS, Rajadhyaksha S, Chhaya S.
    Natl Med J India; 2004 May 15; 17(2):71-3. PubMed ID: 15141598
    [Abstract] [Full Text] [Related]

  • 15. Results of an outpatient-based stem cell allotransplant program using nonmyeloablative conditioning regimens.
    Ruiz-Argüelles GJ, Gómez-Almaguer D, Ruiz-Argüelles A, González-Llano O, Cantú OG, Jaime-Pérez JC.
    Am J Hematol; 2001 Apr 15; 66(4):241-4. PubMed ID: 11279633
    [Abstract] [Full Text] [Related]

  • 16. Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study.
    Cho BS, Lee S, Kim YJ, Chung NG, Eom KS, Kim HJ, Min CK, Cho SG, Kim DW, Lee JW, Min WS, Kim CC.
    Leukemia; 2009 Oct 15; 23(10):1763-70. PubMed ID: 19440217
    [Abstract] [Full Text] [Related]

  • 17. Rapid achievement of complete donor chimerism and low regimen-related toxicity after reduced conditioning with fludarabine, carmustine, melphalan and allogeneic transplantation.
    Wäsch R, Reisser S, Hahn J, Bertz H, Engelhardt M, Kunzmann R, Veelken H, Holler E, Finke J.
    Bone Marrow Transplant; 2000 Aug 15; 26(3):243-50. PubMed ID: 10967561
    [Abstract] [Full Text] [Related]

  • 18. Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies.
    Pedrazzoli P, Da Prada GA, Giorgiani G, Schiavo R, Zambelli A, Giraldi E, Landonio G, Locatelli F, Siena S, Della Cuna GR.
    Cancer; 2002 May 01; 94(9):2409-15. PubMed ID: 12015766
    [Abstract] [Full Text] [Related]

  • 19. Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regimen in patients with hematologic neoplasias.
    Carella AM, Lerma E, Dejana A, Corsetti MT, Celesti L, Bruni R, Benvenuto F, Figari O, Parodi C, Carlier P, Florio G, Lercari G, Valbonesi M, Casarino L, De Stefano F, Geniram A, Venturino M, Tedeschi L, Palmieri G, Piaggio G, Podestà M, Frassoni F, Van Lint MT, Marmont AM, Bacigalupo A.
    Haematologica; 1998 Oct 01; 83(10):904-9. PubMed ID: 9830799
    [Abstract] [Full Text] [Related]

  • 20. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.
    Carella AM, Cavaliere M, Lerma E, Ferrara R, Tedeschi L, Romanelli A, Vinci M, Pinotti G, Lambelet P, Loni C, Verdiani S, De Stefano F, Valbonesi M, Corsetti MT.
    J Clin Oncol; 2000 Dec 01; 18(23):3918-24. PubMed ID: 11099321
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.